Amgen Inc (FRA:AMG)
€ 304.75 5.05 (1.69%) Market Cap: 161.98 Bil Enterprise Value: 209.58 Bil PE Ratio: 41.65 PB Ratio: 23.23 GF Score: 91/100

Amgen Inc and Kyowa Kirin Co Ltd Collaboration on KHK4083 and LUMAKRAS FDA Approval Conference Call Transcript

Jun 01, 2021 / 12:00PM GMT
Release Date Price: €191.9 (-2.07%)
Operator

My name is Crystal, and I will be your conference facilitator today for Amgen's conference call on the approval of LUMAKRAS and the collaboration with Kyowa Kirin. (Operator Instructions)

I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may begin.

Arvind Sood
Amgen Inc. - VP of IR

Crystal, thank you. Good morning, everyone. Thanks for joining us this morning for this call. We have not 1, but 2 topics to discuss today. You may have seen this morning that we announced an agreement to jointly develop and commercialize a novel molecule for atopic dermatitis. We had set up this call initially, of course, to discuss the approval of LUMAKRAS, our first-in-class KRAS G12C inhibitor.

So to discuss these topics further, I'm joined today by Peter Griffith, our CFO; Dave Reese, our Head of R&D; and Murdo Gordon, our Head of Global Commercial Operations. Each will make brief prepared comments, and we shall have plenty of time for Q&A.

So with that, I would like to turn the call over to Peter

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot